英科醫療(300677.SZ):深創投及淄博創新減持實施完畢 合計減持3.82%股份
格隆匯4月23日丨英科醫療(300677.SZ)公佈,公司近日收到深創投和其關聯方淄博創新的《持股5%以上股東減持計劃實施完畢的告知函》。2019年9月24日發佈減持計劃,截止目前,減持時間已結束。並於2020年2月13日發佈大宗減持計劃,截止目前,尚未到期。此次告知擬同時結束此兩次減持計劃。
2019年9月24日-2020年4月22日,深創投及淄博創新通過集中競價方式減持公司股份759.01萬股,佔公司總股本的3.82%,其中深創投減持公司股份588.01萬股,佔公司總股本的2.96%;淄博創新減持公司股份171萬股,佔公司總股本的0.86%。考慮到由於總股本變化導致的被動減持影響後,深創投持有公司股份1037.27萬股,佔公司總股本4.76%。淄博創新持有公司股份466.056萬股,佔公司總股本2.14%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.